ANN ARBOR—Officials at Endra Life Sciences Inc. (Nasdaq: NDRA) announced the issuance of Eurpean Patents 3668382 and 36614116 for, respectively, “Method and System for Estimating Fractional Fat Content of an Object” and “Method for Estimating Fractional Fat Content of an Object.”
Endra uses the technologies in its Thermo Acoustic Enhanced Ultrasound (TAEUS) system, which visualizes tissue like an MRI—but at 1/50th the cost, and in the patient setting.
“These two European patents further strengthen our intellectual property estate and advance our strategy to develop optimized hybrid ultrasound and thermoacoustic imaging systems with our proprietary TAEUS® technology in areas with unmet clinical needs,” said Endra CEO Francois Michelon. “We continue to enhance our intellectual property portfolio to protect our technology in priority global markets. Our portfolio currently stands at 89 assets, which we define as patents issued, filed or in preparation.”
Company officials say Taeus is initially focused on the measurement of fat in the liver as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and inflammation (NASH), chronic liver conditions that affect over one billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, Endra is exploring several other clinical applications of Taeus, including visualization of tissue temperature during energy-based surgical procedures. For more information, please visit www.endrainc.com.